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FIELD OF THE INVENTION
The present invention relates to a novel method for preparing a polypeptide-chelator. More particularly, the invention relates to a novel method for preparing the tripeptide-chelator, glycyl-tyrosyl-(N-e-diethylene triaminepentaacetic acid)lysine ("GYK-DTPA") or glycl-tyrosyl-(N-e-diethylenetriaminepentaacetic acid )lysine hydrochloride ("GYK-DTPA HCl") with the use of t-butyloxycarbonyl (Boc) protecting groups.
Chelators are organic compounds that are able to donate electrons and combine by coordinate bonding which may be used to form conjugates with a variety of 60 proteins, peptides or glycoprotein substances. Polypep tide-chelators are just one example of chelator interme diates which can be used to covalently link a chelator in order to form a conjugate. Polypeptide chelators may also be used alone to form polypeptide complexes with metal ions. More particularly, GYK-DTPA is a poly peptide-chelator which is useful in preparing such metal ion complexes. These complexes are useful for the de 65 2 livery of metal ions which may be radioisotopes or another detectable ion, to target sites in vitro or in vivo.
BACKGROUND OF THE INVENTION
A method of synthesis of a particular polypeptide chelator described herein, GYK-DTPA (glycyl-tyro syl-(N-e-diethylenetriaminepentaacetic acid)lysine), has been disclosed in U. S. Pat. No. 4, 741, 900 to Alvarez et al. This synthesis however, depends upon the utilization of the base-cleavable 9-fluorenylmethyloxycarbonyl (Fmoc) protecting group. This strategy has several disadvantages. First, the process is costly due to the use of the expensive Fmoc protecting group and to the labor-intensive preparative HPLC chromatographic purification of end products required to obtain a puri fied homogeneous product. Secondly, premature loss of the Fmoc group and byproduct formation during scheduled Fmoc removal and DTPA coupling are problematic. The lack of easily purified intermediates necessitates the accumulation of side products, and a preparative high-pressure liquid chromatographic sepa ration is required. In an attempt to address these short comings, a new synthesis of GYK-DTPA utilizing the acid-cleavable t-butyloxycarbonyl (Boc) amino protec tion was devised.
According to U.S. Pat. No. 4,741,900 to Alvarez et al., GYK-DTPA was synthesized as follows: the initial peptide reactant N-Fmoc-glycyl-(O-benzyl-tyrosyl-(e-N-carbobenzyloxy) lysine was prepared according to standard solid phase synthetic methods described by Baranz and Merrifield. In The Peptides, Vol. 2, Gross and Meienhoffer (ed.), Acad. press, New York, pp. 1980 . The derivatized peptide was cleaved from the resin and partially deblocked by bubbling hydrogen bromide (HBr) gas through a suspension of the reaction mixture in trifluoracetic acid containing methoxyben zene (a fifty-fold molar excess over tyrosine) for 60 minutes at room temperature. The resin was removed by filtration and the filtrate evaporated to dryness. The residue was dissolved in a minimum amount of metha nol, and the product precipitated with ether and used without further purification.
One mole N-Fmoc-glycyl-tyrosyl-lysine in DMF was reacted with 1 mole DTPA mixed anhydride prepared as described in Krejcarek et al., Biochem. Biophys. Res. Comm. 77:581-585 (1977) ) in which diisopropyle thylamine was used for 30 minutes at -15°C., and then maintained at room temperature for 1 hour. The solvent was removed by rotary evaporation and the oily residue dissolved in a small aliquot of DMF. Distilled water was added to precipitate the Fmoc-GYK-DTPA pro duced. The Fmoc group was removed by addition of an equal volume of 40% dimethylamine in DMF to a solu tion of Fmoc-GYK-DTPA in DMF, followed by incu bation for 30 minutes at room temperature. The solvent was evaporated to dryness and the residue taken up in distilled water. The crude product was purified by ex traction with ethyl acetate and the resulting aqueous solution of GYK-DTPA was lyophilized to dryness.
More recently, Alvarez et al., in Antibody-Mediated Delivery Systems, John D. Rodwell, Ed., Marcel Dek ker, Inc., New York, (1988), ch. 10, pp. 306-309 de scribed the synthesis of GYK-DTPA as summarized below. GYK-DTPA was prepared starting with a com mercially-available dipeptide, glycyl-tyrosine. The amino terminus of the glycyl-tyrosine starting material was protected by reaction with 9-fluorenylmethyl suc cinimidyl carbonate (Fmoc-OSu), to provide the corre H1312 3 sponding urethane. Subsequently, a peptide-coupling reaction was performed with N-e-benzyloxycarbonyl lysine methyl ester (H-Lys(e-CBZ)-OMe) utilizing the coupling reagents dicyclohexylcarbodiimide and 1 hydroxybenzotriazole (DCC/HOBt). The resulting tripeptide derivative was fully-protected GYK. The urethane protection at the e-amino group of the lysine side-chain was cleaved through the agency of hydro bromic acid in acetic acid, providing the Fmoc-GYK OMe hydrobromide salt, whose amino and carboxy termini remain protected.
The N-Fmoc-GYK(OMe)-HBr and diisopropyle thylamine in dry DMF were then reacted with a DTPA mixed anhydride which was prepared by modification of the method of Krejcarek et al. Biochem. Biophys. Res. Comm. 77: 581-585 (1977) at about 0° C. for about two hours. The reaction mixture was evaporated and the crude Fnoc-GYK-(OMe)-DTPA solid was dis solved in DMF and 40% dimethylamine in water to remove the Fmoc protecting group. The methyl pro tecting group was then removed by saponification in 1N NaOH. The final product, GYK-DTPA was isolated using preparative C-18 reverse phase HPLC using a gradient of 0.1% TFA and acetonitrile. As a result of the Fmoc procedure's multiple prob lems: high cost, labor-intensive preparative HPLC chromatographic purification of the end product, the potential premature loss of the Fmoc group and by product formation during Fmoc removal and DTPA coupling, the lack of easily purified intermediates neces sitating the accumulation of side products and the re quirement of preparative high-pressure liquid chro matographic separation there remains a need for, a new method for synthesis to remedy and/or avoid these problems. . 
where R is a linker from 1-25 carbon atoms and which can include nitrogen and/or carboxyl or other groups which do not denature proteins or peptides. It is an object of the present invention to provide a novel synthesis which provides the benefit of using inexpensive starting materials, thereby avoiding the costly use of dipeptides and Fmoc protection reagents.
It is a further object of the present invention to utilize inexpensive reagents and solvents throughout the pro cess. In addition, most of the solvents used in this novel method are volatile and are amenable to solvent recov ery, thereby further reducing cost. Another object of the present invention is to minimize the use of DMF which is undesirable.
It is a further object of the present invention to pro vide stable intermediates which can be easily isolated in excellent purity. The ability to purify these intermedi ates obviates the need for extensive end-product purifi cation.
In addition it is a further object of the present inven tion to eliminate the need for a preparative HPLC to purify intermediates or final products.
SUMMARY OF THE INVENTION
According to the present invention, a novel process for preparing GYK-DTPA and/or GYK-DTPA HCl utilizing acid-cleavable t-butyloxycarbonyl (Boc) pro tecting groups is described. In one embodiment of the present invention, an inexpensive starting material such as a single amino acid residue is used. The starting amino acid residue possessing suitable side chain protec tion is protected with a suitable protecting group in order to form a carboxy and side chain protected amino acid. This protected amino acid is then reacted with another amino acid residue which has a t-butyloxycar bonyl (Boc) protecting group in the presence of a suit able coupling agent to form a dipeptide having a Boc protected amine terminus and a carboxy terminal ester. The multiply protected dipeptide is then stripped of its Boc protecting group by reaction with an acid in a suitable solvent to form a salt of the dipeptide. The salt of the dipeptide is then reacted with another (Boc) protected amino acid residue in the presence of a suit able coupling agent and base to form a tripeptide with a Boc protected amino terminus and a carboxy terminal ester. It is preferred that the carboxy terminal amino acid residue is lysine. H1312 5 Upon obtaining the desired tripeptide, the tripeptide is treated with appropriate reagents to remove two of the protecting groups to form a partially deprotected polypeptide having a Boc protected amino terminus. According to a preferred embodiment, the tripeptide is reacted with H2 in the presence of a catalyst to remove benzyl ester and side chain carbobenzyloxy protecting groups. Upon partial deprotection, the polypeptide is reacted with a suitable DTPA derivative at the side chain to form a Boc-protected tripeptide-DTPA. Fi nally the Boc protected tripeptide-DTPA is reacted with an acid to remove the Boc protecting group from the amino terminus to form the desired tripeptide DTPA in its acid salt form.
The GYK-DTPA prepared by the method of the invention is particularly useful for forming conjugates and metal ion complexes for a variety of in vitro appli cations as well as in vivo therapeutic and diagnostic applications known to those skilled in the art.
DEFINITIONS
As used throughout the present application, the term "suitable solvent' is meant to encompass solvents which are appropriate for the reactants and reagents used in each corresponding step which will be apparent to one skilled in the art. Examples of preferred solvents used in the present process include, but are not limited to, toluene, ethyl acetate, methanol, ethanol, isopropyl alcohol, dioxane, dimethoxyethane, dimethly forma mide methylene chloride, tetrahydrofuran, etc.
As used throughout the present application, the term "suitable coupling agent" is intended to encompass an agent which is capable of facilitating the coupling of two amino acid residues in order to form an amide bond. Such suitable coupling agents are selected from the group consisting of 1-ethyl-3-(3-dimethylamino propyl)-carbodiimide ("EDCI'), dicyclohexylcarbodi imide ("DDC'), carbonyl dimidazole, 1-ethoxycarbo nyl-2-ethyloxy-1,2-dihydroquinoline ("EEDQ"), ben zotriazol-1-yloxytris (dimethylamino)phosphonium hexafluorophosphate ("BOP"), etc.
As used throughout the present application, the term "suitable catalyst' is intended to encompass a catalyst which is used in hydrogenation reaction such as known by those skilled in the art. Examples include, but are not limited to, palladium on carbon, platinum on carbon, platinum oxide etc. In a preferred embodiment of the present invention, the term "suitable catalyst" refers to palladium on carbon.
As used throughout the present application, the term "suitable acid' is meant to encompass inorganic and organic acids, as known to those skilled in the art which are appropriate for the transformation which is to oc cur. Examples of suitable acids as used in the present invention include, but are not limited to, gaseous HCl, aqueous HCl, HCl in an organic solvent, trifluoroacetic acid, methane sulfonic acid, benzenesulfonic acid, p-tol uene sulfonic acid, etc. In a preferred embodiment of the present invention, "suitable acid' refers to gaseous HCl dissolved in a suitable solvent. Arabic labels denote identification of nonequivalent methylene carbons in the DTPA backbone.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to a novel method for preparing a tripeptide-DTPA chelator utilizing acid-cleavable t-butyloxycarbonyl (Boc) protecting groups. The tripeptide comprises the amino acid resi dues, glycine, tyrosine and lysine, preferably the car boxy terminal amino acid residue is a lysine. In a partic ular embodiment of the present invention, an inexpen sive starting material such as a single suitable amino acid residue is used. The preferred starting amino acid is lysine, having a protected e-amine group. This amino acid residue protected with a suitable group in the pres ence of a suitable solvent to form a carboxy and side chain protected amino acid. The resulting protected amino acid residue is reacted with another amino acid residue having a t-butyloxycarbonyl (Boc) protecting group, in the presence of a suitable coupling agent, to form a dipeptide having a Boc protected amine termi nus and a protected side chain and carboxy terminus. Boc protected amino acid residues are prepared by methods known to those skilled in the art. An example of one such preparation includes, for example, McKay et al., J. Amer. Chem. Soc. 79, 4686 (1957) .
The Boc-protecting group is then removed from the protected amine group by reacting the dipeptide with a suitable acid in a suitable solvent to form a suitable salt of the dipeptide.
The salt of the dipeptide is then reacted with (Boc) protected amino acid residue in the presence of a suit able coupling agent to form a tripeptide with a Boc protected amine terminus and a protected carboxy ter minus and side chain.
The tripeptide is treated with an appropriate reagent to remove two of the suitable protecting groups to form a deprotected tripeptide having Boc protection at the amino terminus. According to a preferred embodiment; the tripeptide is reacted with H2 in the presence of a catalyst to remove benzyl ester and carbobenzyloxy protecting groups. Both the ease of removal as well as the multiple nature of the removal of the protecting groups are benefits derived from the novel method described herein.
Upon side chain deprotection, the tripeptide can be reacted with the bis-N-hydroxysuccinimide ester of DTPA (DTPA-OSu ester) to form the desired tripep tide-DTPA penultimate adduct. Finally the tripeptide DTPA penultimate adduct is deprotected by reaction with an acid to form the desired unprotected tripeptide DTPA in its acid salt form.
In another embodiment described herein, the inex pensive starting material used is a N-e-carbobenzyloxy lysine. This starting material has an unprotected car boxy terminus and one protected and one unprotected amine group. This starting material is reacted with a suitable alcohol in the presence of a suitable solvent to form a carboxy protected N-e-carbobenzyloxy lysine. The carboxy protected N-e-carbobenzyloxy lysine is then reacted with a tyrosine residue having a t-butylox ycarbonyl (Boc) protecting group in the presence of a suitable coupling agent to form a dipeptide Boc-tyro sine-(N-e-CBZ)-lysine benzyl ester, i.e., having a Boc protected amine terminus and an ester protected car H1312 7 boxy terminus. Any suitable coupling agent known to those skilled in the art can be used such as DDC or EDCI. The preferred coupling agent is EDCI. The Boc protecting group is then removed from the amine termi nus (while the carboxy and side chain protecting groups remain intact) by treatment with a suitable acid in a suitable solvent which forms an acid salt of the dipep tide. The preferred acid for this step is gaseous HCl in ethyl acetate, however, other acids and solvents may be used as appropriate for the transformation. This is followed by reacting the hydrochloride salt of the dipeptide with a glycine residue having a Boc pro tecting group in the presence of a suitable coupling agent and base to form a tripeptide having a Boc protected amine terminus and a protected carboxy ter minus. The preferred coupling agent is EDCI which is used in a suitable solvent such as methylene chloride. The tripeptide is then treated with hydrogen gas in the presence of a suitable catalyst in a suitable solvent in order to remove the carboxy and side chain protection and to form a partially deprotected tripeptide (Boc GYK-OH). The preferred catalyst is palladium on car bon. Suitable solvents include lower alcohols such as methanol or ethanol. The preferred solvent is ethanol. The Boc-GYK tripeptide is then reacted with the chela tor to form a Boc-protected GYK-DTPA. Finally, the Boc-protected GYK-DTPA is reacted with an acid to remove the Boc protecting group from the Boc pro tected amine terminus to form a GYK-DTPA acid salt.
The process of the invention is uniquely designed such that this step in fact deprotects two functionalities simultaneously leading to greater cost effectiveness and ease.
SYNTHESIS OF GYK-DTPA
In a preferred embodiment of the present invention, a protected N-e-carbobenzyloxy lysine 1 having an un protected carboxy and amine terminus is reacted with benzyl alcohol in toluene at about 110-about 120° C. in order to form a carboxy protected N-ecarboben zyloxy lysine ester 2. Subsequently, a tyrosine residue having a Boc protecting group is then reacted with the carboxy protected N-e-carbobenzyloxy lysine through a 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide me diated coupling to form a dipeptide Boc tyrosine (N-e-CBZ) lysine benzyl ester having a Boc protected amine terminus and protected carboxy terminus 3. This opera tion, unlike the coupling performed in the Fmoc-based approach, requires no auxiliary reagents, such as HOBt. The Boc protecting group is then conveniently re moved from the Boc protected amine terminus by treat ment with HCl in ethyl acetate to form a hydrochloride salt of the tyrosine-lysine dipeptide 4. The reaction is preferably carried out using gaseous HCl in ethyl ace tate at a temperature from about 0° C. to about 25 C. However, a temperature of about 0°C. is preferred. The hydrochloride salt of the dipeptide is obtained in a suffi ciently high purity which eliminates the need for fur ther purification at this step.
The production of the hydrochloride salt of the di peptide is followed by a reaction with a glycine residue having a Boc protecting group through a 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide mediated coupling (EDCI). The reaction product is a tripeptide (GYK) having a Boc protected amine group 5. The tripeptide (GYK) is then reacted with hydrogen gas in the pres ence of a palladium on carbon in an ethanol solvent at a temperature sufficient to form a partially deprotected tripeptide Boc-GYK-OH 6. Again, the synthesis is de signed to allow for the removal of two of the protecting groups simultaneously and easily. The tripeptide is formed in high yield as a crystalline solid. The pro tected trieeptide intermediate may optionally be further purified by recrystallization. The partially deprotected tripeptide Boc-GYK is then reacted through an acyla tion with diethylenetriaminepentaacetic disuccinindyl ester to form Boc-GYK-DTPA 7. The product is formed in high yield and may optionally be purified using successive recrystallizations from an isopropyl alcohol/methanol mixture. Finally, the Boc protecting group is removed from the Boc protected amine termi nus with aqueous HCl 8.
Crude GYK-DTPA may optionally be passed through a low-pressure glass C18 column.
It is possible that the column step be avoided if the penultimate intermediate 7 is prepared in very high purity, e.g. by recrystallization.
There are therefore two methods of rroducing GYK DTPA of acceptable purity by this approach: 1) attain ing high purity in the penultimate intermediate 7 by recrystallization, 2) purifying end product 8 with low pressure C18 chromatography.
The overall Boc approach offers higher yield throughout, since there is no need for the high pressure liquid chromatographic purification at the end. The yields are high and product purification requires simple synthetic operations.
USES FOR TRIPEPTDE-DTPA
As mentioned above the tripeptide-chelators pre pared by the method of the invention are useful in at taching metal ions, such as radioisotopes, to proteins, peptides or glycoprotein substances. As used in the present application, the term a "protein, peptide or glycoprotein substance' is intended to encompass pro teinaceous substances, including non-glycosylated pro teins, glycoproteins, proteoglycans, etc., as well as pep tidyl, polypeptidyl and glycopeptidyl substances. As such, the term includes polyclonal serum immunoglob ulins, monoclonal antibodies, fragments of monoclonal antibodies having at least a portion of an antigen bind ing region including such as Fv, F(ab')2, Fab, and Fab' fragments, single chain antibodies, chimeric or human ized antibodies, complementarily determining regions (CDRs), etc., serum complement components, en zymes, cell surface histocompatibility antigens, cell surface receptors, peptide or proteinaceous hormones, proteins or peptides which bind to cellularreceptors, and molecular recognition units as that term is de scribed in International Publication No. WO 90/07713 published Jul. 12, 1990, incorporated herein by refer ence. Attachment of the tripeptide-chelator to a protein, peptide or glycoprotein substance forms a conjugate. The conjugates are useful to prepare metal ion com plexes for use as in vivo therapeutics as well as in vivo and in vitro diagnostics. Specifically, the complexes may be used for detection or delivery of labeled metal ions in. for imaging of specific tissues, for therapy at specific tissue or organ sites and immunological assays as described, for example, by Alvarez et al. U.S. Pat. No. 4,741,900. Attachment of the tripeptide-chelator to . a protein, peptide or glycoprotein substance forms a conjugate. Chelation of a metal ion to the conjugate forms a metal ion complex.
In order to more fully illustrate the nature of the invention and the manner of practicing the same, the H1312 following examples are provided, which are not to be construed as limiting the remainder of the disclosure or the scope of the invention in any way whatsoever. A suspension of 48.69 g (174 mmol) of (N-e-carboben zyloxy)lysine (Bachem, Inc.) in a solution of p-toluene sulfonic acid (33.04 g, 174 mmol) in toluene (500 mL) and benzyl alcohol (330 mL) was heated to reflux under a Dean-Stark separator. As reaction progressed the solution became homogeneous. Reflux was continued for 22 hr, at which time 6.6 mL of water (106% of theoretical) had collected. The bulk of the toluene was distilled out of the reaction mixture at atmospheric pressure, then the solution was concentrated by distilla tion under reduced pressure until 750 mL (90%) of the mixture of solvents had been collected. The residue was diluted with EtOAc (800 mL), chilled in an ice bath, and treated with water (200 mL), 2N NaOH (87 mL), and brine (200 mL). A small amount of flocculent pre cipitate was removed by filtration, and the pH of the aqueous phase was adjusted to 10 with 2N NaOH. The organic phase was washed with brine, dried over MgSO4, filtered to remove dryinq agent, and cooled to ice-bath temperature. Anhydrous HC was bubbled through the solution for 5 minutes, resulting in the for nation of a copious white precipitate. Stirring was con tinued for an additional 5 minutes, then N2 was bubbled through the mixture for 20 minutes to dispel HCl. A suspension of lysine derivative 2 (40.65 g, 100 mmol) in CH2Cl2 (350 mL) was treated with diiso propylethylamine (17.5 mL, 100 mmol) and the result ing solution was cooled to 0 C. N-t-Butyloxycarbonyl tyrosine (Vega, 28.10 g, 100 mmol) was added in one portion, followed by 1-ethyl-3-(3-dimethylamino propyl)carbondiimide (Sigma, 21.09 g, 100 mmol). The resulting suspension cleared to a homogeneous solution upon stirring at 0° C. After 18 h, the reaction solution was washed with saturated NaHCO3, then 1N HCl, and 27.9, 28.8, 30.4, 36.8, 42.1, 43.2, 52.0, 53.5, 65.1, 65.8, 78.1, 115.0, 127.7, 127.8, 127.9, 128.1, 28.4, 128.5, 130 Preparation of Tyrosyl-(N-e-benzyloxycarbonyl)lysine benzyl ester hydrochloride 4 A suspension of the tyrosyl-lysine derivative 3 (59.71 g, 96.15 mmol) in EtOAC (750 mL) was cooled to 10 C. and anhydrous HC1 was bubbled through for 20 min. Isopropyl alcohol (500 mL) was added and the resulting homogeneous solution was stored at rt for one hour. 4, 28.9, 30.5, 36.0, 52.2, 53.4, 65.1, 66.0, 115.2, 124.6, 124.7, 127.6, 127.8, 127.9, 128. 1, 128.3, 128.4, 130.4, 130.5, 35.8, 137.2, 156.0, 156.5, 168.3, 171. 2; FAB+ MS m/z 534.5 (M-H, Cl. counterion not detected). Anal. Calcd. for C3oH35N3O6 1.25 HCl: C, 62.21; H, 6.31; N, 7.25. Found: C, 62.13; H, 6.25; N, 7.30, 7.5 EXAMPLE 4 Preparation of (t-Butyloxycarbonyl)glycyl-tyrosyl-(N-e-benzylox ycarbonyl)lysine benzyl ester 5
A suspension of tyrosyl-lysine derivative 4 (13.69 g, 24.7 mmol) in CH2Cl2 (80 mL) was treated with diiso propylethylamine (4.3 mL, 24.7 mmol) and the resulting solution was cooled to 0° C. 0, 28.3, 29.7, 31.4, 36.9, 40.8, 44.5, 52.3, 54.1, 67.0, 67.1, 80.6, 115.79, 127.0, 128.2, 128.5, 128.6, 130.4, 135.3, 136.3, 155.8, 156.9, 169.7, 170.6, 171.4 Preparation of (t-Butyloxycarbonyl)glycyl-tyrosyl-lysine 6 25
A solution of the glycyl-tyrosyl-lysine derivative 5 (16.80g, 24.35 mmol) in warm ethanol (40' C., 750 mL) was treated with 10% Pd/C (Aldrich, 0.84 g) and H2 gas was bubbled in with vigorous stirring for five hours. 27.1, 28.0, 28.1, 31.8, 36.8, 43.1, 53.7, 54.1, 78.0, 114.8, 127.5, 127.6, 128.3, 130.0, 155.6, 155.8, 169.0, 169, 1740 ; FAB+ MS m/z 467 (M--H), 367 (M +H -Me3CO2C). Anal. Calcd. for C22H34N4O7: C, 56.62; H, 7.35; N, 12.01. Found: C, 56.70; H, 7.35; N, 12.02. 7.7 EXAMPLE 6 Preparation of (t-Butyloxycarbonyl)glycyl-tyrosyl-(N-e-diethylene trianine-pentaacetic acid)lysine 7 35 45 Method A. A solution of N-hydroxysuccinimide 50 (27.1 g, 235.8 mmol) in DMF (230 mL) was treated with DTPA dianhydride (42.1 g, 117.9 mmol) and warmed to 70° C. until all of the anhydride reacted and dissolved. The solution was cooled to rt, and a solution of (tbutyloxycarbonyl)glycyl-tyrosyl-lysine 6 (11.0 g, 23.60 mmol) in water (65 mL) was introduced. After 4 hr at rt, HPLC analysis indicated that starting tripeptide had been consumed. Excess dianhydride was destroyed and the resulting DTPA byproduct was removed by dilut ing the reaction mixture with MeOH (250 mL) and water (60 mL), stirring for 1 hr, and filtering. Solvents were removed by rotary evaporation and the residue was triturated with THF (2x300 mL) and MeCN (30 mL). This operation deposits the product as a white solid and removes residual DMF and most of the N hydroxysuccinimide, leaving 19.0 g (95.6%) of a white solid. An analytical sample was prepared by three suc cessive recrystallizations from methanol/isopropyl al 55 65 12 cohol. Purity: 95.9% (HPLC, System B); MP 160 C. (decomposes over a large temperature range); H NMR
